Our results implicate acid ceramidase in the pathogenesis of GBA1-associated PD, suggesting that this enzyme is a potential therapeutic target for treating synucleinopathies caused by GCase deficiency. This evidence concerns the gene GBA1 and hyperinsulinemic hypoglycemia, familial, 4.